LBP was founded in 2005 and focuses on tumor screening and accurate diagnosis. 

Now we have independently developed a series of reagents and supporting equipment, mainly in the department of pathology. The product lines of liquid-based cytology (LBP), polymerase chain reaction (PCR), immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) have been established, covering the clinical needs of tumor screening and diagnosis at different diagnostic levels from cell morphology to protein expression and gene detection. Some of our products have been certified by CE , British Standards Institute (BSI) and Japanese Ministry of Health, Labor and Welfare. It is one of the enterprises with the most abundant technology platform and the largest product variety in the cancer screening and diagnosis industry in China. 

In order to improve the "automation, standardization, digitalization and intellectualization" level of pathology department, LBP has launched a series of digital pathology products, among which pathological medical image analysis and processing system and automatic digital slice scanning system have been certified and marketed. At the same time, LBP actively responds to the national policy of quality medical resources sinking and promoting hierarchical diagnosis and treatment, constantly expands pathology service business, and helps improve the diagnostic ability of pathology departments in grassroots hospitals. In order to promote the accurate matching of drugs for cancer patients, the company is also actively expanding the business of accompanying diagnosis for pharmaceutical companies. 

LBP always adheres to the purpose of "creating value for society and customers, in order to realize the value of employees and enterprises", commits itself to becoming a leading enterprise in the field of pathological diagnosis, and realizes the corporate vision of "Benefiting society with precision medicine diagnosis".